JNX1001 AS A TREATMENT FOR ALS

JNX1001 is a small molecule, neurotrophic factor modulator that has demonstrated efficacy in several preclinical models of amyotrophic lateral sclerosis (ALS) including efficacy in two independent studies in the mSOD1^{G93A} mouse, the 'gold-standard' preclinical model of ALS. JNX1001 has an excellent safety profile in humans, with an IND to allow an immediate clinical trial in ALS and market-protected by Orphan Designation.



THE OPPORTUNITY

ALS – The problem

ALS is a fatal neurodegenerative disorder that is characterised by a loss of motor neurons and life expectancy from diagnosis is approximately 14 months. There is no effective treatment for ALS and the only licenced drug, riluzole, extends survival by 3-6 months.

ALS is classed as an Orphan Disease and affects ~30,000 people in the US with more than 5,600 new cases diagnosed each year. A therapy for ALS could have peak sales of US$500M p.a.

JNX1001 – The solution

JNX1001 is a small molecule that has been through extensive evaluation. In preclinical efficacy studies, JNX1001 was 4-fold more effective than riluzole, in extending survival in mSOD1^{G93A} mice. JNX1001 also protected motor neurons and improved nerve and muscle function. If these effects were replicated in the clinic JNX1001 would be a highly efficacious compound.

JNX1001 has an excellent safety profile demonstrated in pharmacology, toxicology and clinical studies and has an open IND for ALS. JNX1001 could quickly be progressed into long-term Phase II clinical studies.

THE INVESTMENT

Junaxo Inc. is a drug development company located in Toronto, Canada. Junaxo is currently seeking an investment of US$4.5M that will allow it to evaluate the effect of JNX1001 in people with ALS in a Phase IIa clinical study.

DEVELOPMENT PATH AND MARKET SIZE

Junaxo Inc. has EU and US Orphan Disease Designation for JNX1001 which would allow an accelerated development path. Following the initial Phase IIa clinical study a Phase II study would be performed which would cost ~US$20M. Following this study, market approval for JNX1001 in ALS would be sought.

Riluzole, the only FDA approved treatment for ALS had global sales of US$64M in 2012 and has since become off-patent. The market size for ALS will be driven by an effective drug and it is estimated that a drug that could extend life-expectancy by 24 months then the market size for ALS would be US$2-4Bn.